Long-Term Effects of Suramin on Renal Function in Streptozotocin-Induced Diabetes in Rats

In short-term diabetes (3 weeks), suramin, a drug used clinically, affects renal function and the expression of vascular endothelial growth factor A (VEGF-A), which may be involved in the pathogenesis of diabetic nephropathy, the main cause of end-stage renal disease. In the present study, we evaluated the long-term (11 weeks) effects of suramin (10 mg/kg, i.p., once-weekly) in diabetic rats. Concentrations of VEGF-A, albumin, soluble adhesive molecules (sICAM-1, sVCAM-1), nucleosomes, and thrombin–antithrombin complex (TAT) were measured by ELISA, total protein was measured using a biuret reagent. Glomerular expression of VEGF-A was evaluated by Western blot, mRNA for VEGF-A receptors in the renal cortex by RT-PCR. The vasoreactivity of the interlobar arteries to acetylcholine was assessed by wire myography. Long-term diabetes led to an increased concentration of VEGF-A, TAT, and urinary excretion of total protein and albumin, and a decrease in the concentration of sVCAM-1. We have shown that suramin in diabetes reduces total urinary protein excretion and restores the relaxing properties of acetylcholine relaxation properties to non-diabetic levels. Suramin had no effect on glomerular expression VEGF-A expression and specific receptors, and on sICAM-1 and nucleosomes concentrations in diabetic rats. In conclusion, the long-term effect of suramin on the kidneys in diabetes, expressed in the reduction of proteinuria and the restoration of endothelium-dependent relaxation of the renal arteries, can be considered as potentially contributing to the reduction/slowing down of the development of diabetic nephropathy.

• Publication year

  2023

• Venue

  International Journal of Molecular Sciences

• Publication date

  2023-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms241914671PMID 37834118PMCID 10572378
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suramin Affects the Renal VEGF-A/VEGFR Axis in Short-Term Streptozotocin-Induced Diabetes

  2023cited by this paper
• Endothelial Cells: Potential Novel Regulators of Renal Inflammation.

  2022cited by this paper
• The polyanionic drug suramin neutralizes histones and prevents endotheliopathy

  2021cited by this paper
• Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats

  2021cited by this paper
• New progress in drugs treatment of diabetic kidney disease.

  2021cited by this paper
• A Plasma Creatinine- and Urea-Based Equation to Estimate Glomerular Filtration Rate in Rats.

  2020influential reference
• Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role

  2020cited by this paper
• Performance evaluation of thrombomodulin, thrombin‐antithrombin complex, plasmin‐α2‐antiplasmin complex, and t‐PA: PAI‐1 complex

  2019cited by this paper
• Endothelium structure and function in kidney health and disease

  2019cited by this paper
• VEGF in Signaling and Disease: Beyond Discovery and Development.

  2019cited by this paper
• 100 Years of Suramin

  2019cited by this paper
• Diagnosis of diabetic kidney disease: state of the art and future perspective.

  2018cited by this paper
• Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis

  2018cited by this paper
• Molecular complexity of the major urinary protein system of the Norway rat, Rattus norvegicus

  2018cited by this paper
• Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

  2017cited by this paper
• VEGF and the diabetic kidney: More than too much of a good thing.

  2017cited by this paper
• Antiangiogenic Therapy for Diabetic Nephropathy

  2017cited by this paper
• Vascular Growth Factors and Glomerular Disease.

  2016cited by this paper
• Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.

  2015cited by this paper
• The major urinary protein system in the rat.

  2014cited by this paper
• Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

  2014cited by this paper
• Suramin: A Potential Therapy for Diabetic Nephropathy

  2013cited by this paper
• Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy

  2013cited by this paper
• Suramin ameliorates collagen induced arthritis.

  2012cited by this paper
• Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat.

  2012cited by this paper
• Vegfa Protects the Glomerular Microvasculature in Diabetes

  2012cited by this paper
• Diabetes-Induced Renal Injury in Rats Is Attenuated by Suramin

  2012cited by this paper
• Suramin inhibits renal fibrosis in chronic kidney disease.

  2011cited by this paper
• Human African trypanosomiasis

  2010cited by this paper
• Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature.

  2009cited by this paper
• Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome

  2008cited by this paper
• In vivo regulation of endothelium-dependent vasodilation in the rat renal circulation and the effect of streptozotocin-induced diabetes.

  2008cited by this paper
• Autocrine VEGF signaling is required for vascular homeostasis.

  2007cited by this paper
• Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat

  2006cited by this paper
• Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction.

  2005cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

  2003cited by this paper
• Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

  2003cited by this paper
• Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.

  2001cited by this paper
• Vascular Endothelial Growth Factor Expression of Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), and E-selectin through Nuclear Factor-κB Activation in Endothelial Cells*

  2001cited by this paper
• Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.

  2001cited by this paper
• Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.

  2000cited by this paper
• Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.

  2000cited by this paper
• Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.

  1999cited by this paper
• Soluble intercellular adhesion molecule-1 (ICAM-1) in serum and urine: correlation with renal expression of ICAM-1 in patients with kidney disease.

  1997cited by this paper
• High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha.

  1997cited by this paper
• Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.

  1996cited by this paper
• Recent research on the biological activity of suramin.

  1993cited by this paper
• Impaired Endothelium‐Dependent Vasodilation in Patients With Insulin‐Dependent Diabetes Mellitus

  1993cited by this paper
• E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.

  1992cited by this paper
• Impairment of endothelium‐dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin‐induced diabetic rats

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

  1984cited by this paper

• No citing papers are available for this paper.